A Clinical Trial of the Relationship Between Anxiety and Lung Function and Respiratory Symptoms in Patients with Asthma, Copd and Copd-Asthma. Assessment of Life Quality

Anxiety is a comorbidity among patients with chronic respiratory diseases such as asthma, COPD and COPD-asthma. Anxiety disorders in this population have a considerable influence on asthma management, because they influence the perception of symptoms, and anxiety related to treatment can influence compliance. Patient noncompliance with treatment for chronic respiratory diseases compromises the success of treatment and the patient’s quality of life, while increasing medical costs. Therefore, the aim of our study was to provide patient-centered care and determine which dimension of anxiety is associated with asthma, COPD and COPD-asthma in the general population after controlling age, background and sex. In order to obtain information on the response to treatment, questionnaires on symptom control (Asthma Control Test (ACT), COPD Assessment Test (CAT)) and asses anxiety using the ASQ questionnaire. The result obtained indicates that no compliant person presented a high score of the dimensions (somatic, behavioral and cognitive dimension.) and predominates of anxiety a low overall score. The symptoms associated with anxiety have a low, medium overall score but also a high score on the first visit. The first and second age categories have a low score in both the behavioral and somatic dimensions. In the age category 3 and 4 are people with low score and medium score behavioral dimension and cognitive dimension. In conclusion we can say that through repetitive control we obtained increased treatment compliance was achieved, leading to improved lung function, symptoms control and therefore reduced anxiety in the case of patients with asthma, COPD and COPD-asthma.